Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
​Cell & Gene therapy Drug R&D Service Platform

Leave a Message

Subscribe to get interesting news delivered to your inbox.

Verification Code
Click switch

cell and gene therapy.jpg

Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). 

Medicilon has established a one-stop research platform for the preclinical R&D of Cell & Gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

Cell & Gene Therapy Preclinical Research Content

Pharmacodynamic Research

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

Pharmacodynamic Studies
❖ Tumor killing rate or proliferation inhibition rate
❖ Expression of IFN-γ
❖ Phenotypic changes of CAR-T cells

Technical Method
❖ Bioluminescent Imaging (BLI)
❖ Flow Cytometry
❖ Immunoassay Technology
❖ Pathology Technology


Pharmacokinetic Research

Cell & Gene therapy products should be analyzed and evaluated according to the specific characteristics of the product, taking into account the actual exposure in non-clinical studies. The bio-distribution of cell & gene therapy products is the distribution, persistence and clearance of gene therapy products in target and non-target tissues in the body.

Technology Platform
❖ Imaging Technology
❖ Flow Cytometry
❖ Immunohistochemistry Technology
❖ Quantitative PCR Technology
❖ ddPCR


Preclinical Safety Studies

Cell & Gene therapy products should be capable of effective introduction/exposure in the relevant animal species. The non-clinical safety studies of cell therapies (such as CAR-T cells) include: cytokine release syndrome (CRS), reversible neurotoxicity, B cell reduction, on-target/off-tumor, CAR- T cell tumorigenicity, etc.

Technology Platform
❖ General Toxicology
❖ Immunogenicity
❖ Immunotoxicity
❖ Reproductive toxicity
❖ Genotoxicity
❖ Neurotoxicity
❖ Carcinogenicity

Case Studies


Medicilon Cell & Gene Therapy Drug Service Qualification

Medicilon Toxicology Research Department has been granted AAALAC Accreditation and GLP certificate of NMPA and passed the on-site evaluation, with research globally recognized capabilities to support filing programs for multiple countries.

Service Modules
❖ Pharmacological/Pharmacodynamic research
❖ Bio-distribution
❖ Immunogenicity
❖ Drug Safety Evaluation

Service Types
❖ Cell Therapy
❖ Oncolytic Virus
❖ Oligonucleotide
❖ Gene Editing

Contact Us
585 Chuanda Rd, Pudong, Shanghai, China, 201299 (Headquarters)
1 Broadway, 9th Fl, Cambridge Innovation Center, Cambridge, MA 02142, US
Kelvinstraat 41b, 6601 HH Wijchen, The Netherlands
Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Relevant News